12:06 PM EST - Prometic Life Sciences Inc. : Has completed a Type C meeting in which the FDA agreed with the Company's proposed action plan for the implementation of additional analytical assays and in-process controls related to Ryplazim™ (plasminogen) manufacturing process. As a result of the feedback received during the Type C meeting, Prometic is finalizing the process performance qualification (PPQ) protocol in anticipation of commencing the manufacturing of additional Ryplazim™ (plasminogen) conformance lots. Prometic Life Sciences Inc.
shares T.PLI are trading up $0.05 at $0.54.
